Targeting JNK pathway may offer new treatment approach for SMA
WHY IT MATTERS
If this JNK pathway blocking approach moves to human trials, it could offer SMA patients a new treatment option, potentially as a combination therapy with existing approved drugs like nusinersen or onasemnogene abeparvovec.
Scientists discovered that blocking a protein pathway called JNK in the body may help treat spinal muscular atrophy (SMA), a disease that weakens muscles. In mice with severe SMA, blocking this pathway reduced how bad the disease got and helped the mice live longer. This new approach could work by itself or combined with medicines that are already approved for SMA.
Targeting a stress-activated signaling pathway may offer a new way to treat spinal muscular atrophy (SMA), either on its own or in combination with existing therapies. Researchers found that blocking the c-Jun N-terminal kinase (JNK) pathway with medications significantly reduced disease severity and extended survival in a mouse model of severe SMA. Unlike approved SMA […] The post Targeting JNK pathway may offer new treatment approach for SMA appeared first on SMA News Today .